ArticleNeurology2019
Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies.
Abstract read
In one paragraph
Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Trial
- Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson's disease.Brain : a journal of neurology · 2026Article
- MIND diet, cerebrovascular health, and cognition among community-dwelling older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Proteome-wide association study of cortical proteins that may provide resilience for late-life disability.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- α-Synuclein in Lewy Body Diseases: Progress, Remaining Challenges and Future Perspectives.Expert reviews in molecular medicine · 2026Review
- One patient, one destiny: A cluster analysis of the Parkinson's progression Markers Initiative (PPMI) cohort.Clinical parkinsonism & related disorders · 2026Article
- Systemic inflammatory index correlates with cerebral small vessel disease in Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Associations of pathologic Parkinson's disease (PD) and co-pathologies with cognitive decline and progression of parkinsonian signs in decedents with subclinical disease.Acta neuropathologica · 2025Article
- Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases.NPJ Parkinson's disease · 2025Article
- Recruitment of Aβ into α‑Synuclein Condensates Catalyzes Primary Nucleation of α‑Synuclein Aggregation.ACS central science · 2025Article
- Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.International journal of molecular sciences · 2025Review
- Physics of Protein Aggregation in Normal and Accelerated Brain Aging.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- Identifying motor resilience proteins associated with motor decline in older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Validating the Accuracy of Parkinson's Disease Clinical Diagnosis: A UK Brain Bank Case-Control Study.Annals of neurology · 2025Article
- Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence.International journal of molecular sciences · 2025Review
- Bone-brain interaction: mechanisms and potential intervention strategies of biomaterials.Bone research · 2025Review
- Does white matter and vascular injury from repetitive head impacts lead to a novel pattern on T2 FLAIR MRI? A hypothesis proposal and call for research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- The centenarian blueprint: lessons in defying Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Temporal Sequence of Incident Mild Cognitive Impairment, Incident Parkinsonism, and Risk of Death in Unimpaired Community-Dwelling Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Aron S BuchmanFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston. Aron_S_Buchman@rush.edu.
Lei YuFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Robert S WilsonFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Sue E LeurgansFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Sukriti NagFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Joshua M ShulmanFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Lisa L BarnesFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Julie A SchneiderFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
David A BennettFrom the Rush Alzheimer's Disease Center (A.S.B., L.Y., R.S.W., S.E.L., S.N., L.L.B., J.A.S., D.A.B.), and Departments of Neurological Sciences (A.S.B., L.Y., R.S.W., S.E.L., J.A.S., D.A.B.), Behavioral Sciences (R.S.W., L.L.B.), and Pathology (Neuropathology) (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; Departments of Neurology, Molecular and Human Genetics, Neuroscience, and Program in Developmental Biology (J.M.S.), Baylor College of Medicine, Houston, TX; and Jan and Dan Duncan Neurological Research Institute (J.M.S.), Texas Children's Hospital, Houston.
Funding
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1MEPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3MRISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4MRisk Factors for Cognitive Decline in African-AmericansR01AG022018 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BARNES, LISA L · 2004 to 2025
$18.2MRacial Differences in Late-Life Cognitive Decline and Risk of Alzheimer's DiseaseRF1AG022018 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BARNES, LISA L · 2016 to 2019
$6.6MImpaired Gait in Older Adults: Pathologies of Alzheimer's disease and Related DisordersR01AG056352 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BUCHMAN, ARON S · 2017 to 2021
$3.5MSpinal cord and brainstem pathology contributions to late-life gait impairmentR01AG047976 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BUCHMAN, ARON S · 2015 to 2019
$2.6MThe Clinical Profile of Parkinson's Disease (PD) PathologyR01NS078009 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI BUCHMAN, ARON S · 2012 to 2016
$2.4MElucidating the Molecular Drivers of Impaired Mobility Within and Outside the CNS in Alzheimer's Disease and Related DisordersR56AG059732 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BUCHMAN, ARON S · 2018 to 2018
$758kNIA NIH HHS P30 AG010161NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG022018NIA NIH HHS R01 AG047976NIA NIH HHS R01 AG056352NIA NIH HHS R56 AG059732NIA NIH HHS RF1 AG022018NINDS NIH HHS R01 NS078009
Abstract
objectiveTo examine whether indices of Parkinson disease (PD) pathology and other brain pathologies are associated with the progression of parkinsonism in older adults.
methodsWe used data from decedents who had undergone annual clinical testing prior to death and structured brain autopsy. Parkinsonism was based on assessment with a modified Unified Parkinson's Disease Rating Scale and a clinical diagnosis of PD was based on medical history. We used a series of mixed-effects models controlling for age and sex to investigate the association of PD pathology (nigral neuronal loss and Lewy bodies) and indices of 8 other brain pathologies with the progression of parkinsonism prior to death.
resultsDuring an average of 8.5 years' follow-up, more than half (771/1,430, 53.9%) developed parkinsonism proximate to death. On average, parkinsonism was progressive (estimate 0.130, SE 0.005,
conclusionThe rate of progressive parkinsonism in older adults with and without a clinical diagnosis of PD is related to the burden of mixed brain pathologies.
Indexed as
Aged, 80 and overBrainDisease ProgressionFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleParkinsonian DisordersProspective StudiesSeverity of Illness Index
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.